EverImmune develops live biotherapeutic products targeting the microbiota to improve cancer immunotherapy responses, with lead candidate Oncobax AK. The company will use funding to run a phase I/II trial in patients undergoing immunotherapy, testing whether daily Oncobax AK pills can reverse AK deficiency and restore responsiveness in primary resistance settings. The trial will recruit 71 NSCLC or RCC patients across 15 hospitals in France and Belgium, including Gustave Roussy. The clinical program uses a companion test to select patients deficient in AK and resistant to immunotherapy. EverImmune is also developing a broader pipeline of bacteria-based adjuvants for other cancers such as breast and colon. Founded in 2016 as a spinoff from Gustave Roussy, the company has seven staff and is part of the ONCOBIOME European program; the article notes that currently only 30% of NSCLC patients and 40% of RCC patients respond to immunotherapy. EverImmune develops live biotherapeutic products (LBPs) that harness the gut microbiota to boost the immune system and restore sensitivity to immune checkpoint inhibitors in cancer patients. Its lead product, Oncobax® AK (Akkermansia), is a lyophilized LBP formulated in delayed-release oral capsules intended as an adjuvant to anticancer immunotherapies. The company plans to start a Phase I clinical trial for Oncobax AK in Q2 2022, targeting non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). The initial trial is planned for 66 patients (33 NSCLC and 33 RCC) with a planned cohort extension of an additional 50 patients to evaluate safety and efficacy. EverImmune was founded in 2016 as a spinoff from Gustave Roussy and is part of ONCOBIOME, an EU-funded program on microbiome and cancer. The company also maintains a broader pipeline of bacterial products with adjuvant potential in other cancers such as breast and colon cancer and has five staff.

Total raised

$9M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2023